Table 1 Demographic and study entry characteristics
Characteristic | Severe acute malnutrition | Mild malnutrition/normal nutrition |
|---|---|---|
N = 25 | N = 27 | |
Sex | ||
Male | 16 (64%) | 13 (48%) |
Age (months) | ||
median, (Q1, Q3) | 19 (13,25) | 18 (12,25) |
6- < 18mo | 11 (44%) | 13 (48%) |
≥ 18mo | 14 (56%) | 14 (52%) |
Cohort subgroup | ||
SAM | 25 (100%) | 0 (0%) |
Mild malnutrition | 0 (0%) | 15 (56%) |
Normal nutrition | 0 (0%) | 12 (44%) |
WHO Clinical Stage | ||
Clinical Stage I | 8 (32%) | 20 (74%) |
Clinical Stage II | 2 (8%) | 4 (15%) |
Clinical Stage III | 5 (20%) | 3 (11%) |
Clinical Stage IV | 10 (40%) | 0 (0%) |
Log10 HIV-1 RNA (copies/mL) | ||
median (Q1, Q3) | 4.8 (4.2,5.6) | 5.6 (4.8,6.1) |
CD4% (screening) | ||
median (Q1, Q3) | 15.0 (9.0,22.6) | 23 (17,31) |
Zinc (ug/dL) | ||
median (Q1, Q3) | 50.4 (41.7,59.8) | 53.1 (47.1,62.5) |
% zinc deficient | 2 (8%) | 0 (0%) |
Selenium (ug/L) | ||
median (Q1, Q3) | 92.7 (77.6,103.9) | 83.2 (64.7,105.6) |
% selenium deficient | 0 (0%) | 0 (0%) |
Albumin (g/L) | ||
median (Q1, Q3) | 35 (31.0,40.0) | 41.7 (36.0,47.0) |
Total protein (g/L) | ||
median (Q1, Q3) | 70.1 (67.1,83.7) | 77.0 (73.2,84.0) |
Therapeutic feed | 25 (100.0%) | 6 (22.2%) |
Any supplements containing zinc | 8 (32.0%) | 4 (14.8%) |